- Home
- JANX vs VVX Comparison
JANX vs VVX Comparison
Compare JANX & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- VVX
- Stock Information
- Founded
- JANX 2017
- VVX 2014
- Country
- JANX United States
- VVX United States
- Employees
- JANX N/A
- VVX N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- VVX Diversified Commercial Services
- Sector
- JANX Health Care
- VVX Consumer Discretionary
- Exchange
- JANX Nasdaq
- VVX Nasdaq
- Market Cap
- JANX 1.6B
- VVX 1.4B
- IPO Year
- JANX 2021
- VVX 2014
- Fundamental
- Price
- JANX $23.60
- VVX $44.81
- Analyst Decision
- JANX Strong Buy
- VVX Buy
- Analyst Count
- JANX 7
- VVX 8
- Target Price
- JANX $94.29
- VVX $65.25
- AVG Volume (30 Days)
- JANX 808.2K
- VVX 223.0K
- Earning Date
- JANX 08-06-2025
- VVX 08-05-2025
- Dividend Yield
- JANX N/A
- VVX N/A
- EPS Growth
- JANX N/A
- VVX N/A
- EPS
- JANX N/A
- VVX 1.29
- Revenue
- JANX $9,336,000.00
- VVX $4,327,514,000.00
- Revenue This Year
- JANX N/A
- VVX $4.02
- Revenue Next Year
- JANX $1,470.82
- VVX $4.80
- P/E Ratio
- JANX N/A
- VVX $34.94
- Revenue Growth
- JANX 28.12
- VVX 7.38
- 52 Week Low
- JANX $22.48
- VVX $41.08
- 52 Week High
- JANX $71.71
- VVX $69.75
- Technical
- Relative Strength Index (RSI)
- JANX 41.60
- VVX 42.44
- Support Level
- JANX $24.45
- VVX $43.80
- Resistance Level
- JANX $27.28
- VVX $45.48
- Average True Range (ATR)
- JANX 1.35
- VVX 1.19
- MACD
- JANX -0.09
- VVX 0.13
- Stochastic Oscillator
- JANX 22.20
- VVX 53.46
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About VVX V2X Inc.
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.